KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBITDA: 2009-2024

Historic EBITDA for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $484.2 million.

  • Biomarin Pharmaceutical's EBITDA fell 123.97% to -$20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.3 million, marking a year-over-year increase of 27.21%. This contributed to the annual value of $484.2 million for FY2024, which is 160.65% up from last year.
  • Biomarin Pharmaceutical's EBITDA amounted to $484.2 million in FY2024, which was up 160.65% from $185.8 million recorded in FY2023.
  • Biomarin Pharmaceutical's EBITDA's 5-year high stood at $484.2 million during FY2024, with a 5-year trough of -$82.3 million in FY2021.
  • For the 3-year period, Biomarin Pharmaceutical's EBITDA averaged around $277.0 million, with its median value being $185.8 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 89.55% in 2021, then spiked by 295.50% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's EBITDA (Yearly) stood at -$43.4 million in 2020, then slumped by 89.55% to -$82.3 million in 2021, then soared by 295.50% to $161.0 million in 2022, then increased by 15.41% to $185.8 million in 2023, then surged by 160.65% to $484.2 million in 2024.